Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carfecillin is a semisynthetic, orally administered penicillin antibiotic of the carboxypenicillin class. It is the phenyl ester prodrug of carbenicillin, designed to improve oral bioavailability compared to its parent compound. After oral administration, it is hydrolyzed in the body to release active carbenicillin. Carbenicillin acts by binding to and inactivating penicillin-binding proteins (PBPs) on bacterial cell membranes, thereby inhibiting cross-linking of peptidoglycan chains essential for bacterial cell wall synthesis. This disruption leads to weakening and lysis of susceptible bacteria. Carfecillin was primarily used for urinary tract infections and shares many properties with other broad-spectrum penicillins[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carfecillin.